Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer – guidance (TA632)

Trastuzumab emtansine is recommended, as an option for adjuvant treatment of HER2+ve early breast cancer in adults who have residual invasive disease in the breast or lymph nodes after neoadjuvant taxane-based and HER2‑targeted therapy.


National Institute for Health and Care Excellence